LEHI, Utah and LOUISVILLE, Ky., April 30, 2025 /PRNewswire/ -- Waystar (Nasdaq: WAY), a provider of leading healthcare payment software, today announced that Chief Executive Officer Matt Hawkins and Chief Financial Officer Steve Oreskovich will speak at two upcoming investor conferences.
Oreskovich will present at the Bank of America Securities Healthcare Conference on Wednesday, May 14, 2025, at 8:40 a.m. PT. Hawkins will present at the William Blair 45th Annual Growth Stock Conference on Tuesday, June 3, 2025, at 12 p.m. CT.
Both presentations will stream live on Waystar's Investor Relations website at https://investors.waystar.com/news-events/events. Recordings will be available on the site afterward.
About Waystar
Waystar's mission-critical software is purpose-built to simplify healthcare payments so providers can prioritize patient care and optimize their financial performance. Waystar serves approximately 30,000 clients, representing over 1 million distinct providers, including 16 of 20 institutions on the U.S. News Best Hospitals list. Waystar's enterprise-grade platform annually processes over 6 billion healthcare payment transactions, including over $1.8 trillion in annual gross claims and spanning approximately 50% of U.S. patients. Waystar strives to transform healthcare payments so providers can focus on what matters most: their patients and communities. Discover the way forward at waystar.com.
Media Contact
Kristin Lee
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investor Contact
Sandy Draper
This email address is being protected from spambots. You need JavaScript enabled to view it.
502-238-9511
| Last Trade: | US$34.99 |
| Daily Change: | 0.34 0.98 |
| Daily Volume: | 918,067 |
| Market Cap: | US$6.100B |
July 30, 2025 July 23, 2025 April 30, 2025 | |
Cue Biopharma is developing the first-ever class of therapeutics for the treatment of cancer that mimic the natural signals, or “Cues”, of the immune system. This novel class of injectable biologics selectively engages and modulates tumor-specific T cells directly within the patient’s body to transform...
CLICK TO LEARN MORE
Amneal Pharmaceuticals is a fully-integrated essential medicines company. We make healthy possible through the development, manufacturing, and distribution of generic and specialty pharmaceuticals. The Company has a diverse portfolio of over 250 products in its Generics segment and is expanding across...
CLICK TO LEARN MORE
